Published 8 hours ago • loading... • Updated 8 hours ago

Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody

Harbour BioMed published online on March 22, 2026, the Phase I trial results of HBM9378 led by Dr. Min Xu in a peer‑reviewed journal.
HBM9378 is a half‑life‑extended anti‑TSLP antibody engineered for half‑life extension and silenced effector function, co‑developed by Harbour BioMed and Kelun‑Biotech to treat asthma and chronic obstructive pulmonary disease .
In the Phase I study, investigators enrolled 50 healthy adult subjects across three dose cohorts, with a 5% ADA incidence and no injection-site reactions, showing Tmax 4.05–14.1 days and half-life 55.0–65.8 days.
Harbour BioMed and Kelun‑Biotech granted Windward Bio AG the global rights outside Greater China; the NMPA approved an IND in China, and the program has advanced to global testing.
The positive Phase I results for HBM9378 mark a significant milestone in our mission to develop innovative therapies for immunological diseases, said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

Insights by Ground AI

27 Articles

The Berkshire Eagle

+26 Reposted by 26 other sources

Center

Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announced the online…

8 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year